帕金森病运动并发症的防治策略

帕金森病运动并发症的认识与处理[J] 刘振国; 临床内科杂志 2011,

浅谈帕金森病治疗的并发症——异动症[J] 刘振国; 中华老年医学杂志 2006, 12

Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta‐analysis of levodopa‐controlled trials[J] M. Chondrogiorgi;A. Tatsioni;H. Reichmann;S. Konitsiotis Eur J Neurol 2014,

Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China.[J] Zhang Zhen-Xin;Chen Honglei;Chen Sheng-Di;Shao Ming;Sun Sheng-Gang;Qu Qiu-Min;Zhang Bao-Rong;Liu Yi-Ming;Xu Qun;Wan Xia;Li Ling;Wen Hong-Bo;Chen Xia;Chen Hai-Bo;Liu Zhen-Guo;Wang Jian;Wang Gang BMC research notes 2014,

Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease[J] C. Warren Olanow;Karl Kieburtz;Olivier Rascol;Werner Poewe;Anthony H. Schapira;Murat Emre;Helena Nissinen;Mika Leinonen;Fabrizio Stocchi; Mov Disord. 2013,

Nonmotor fluctuations in Parkinson disease: Severity and correlation with motor complications[J] Alexander Storch;Christine B. Schneider;Martin Wolz;Yannic Stürwald;Angelika Nebe;Per Odin;Andreas Mahler;Gerd Fuchs;Wolfgang H. Jost;K. Ray Chaudhuri;Rainer Koch;Heinz Reichmann;Georg Ebersbach Neurology 2013,

Summary of the recommendations of the EFNS / MDS ‐ ES review on therapeutic management of P arkinson's disease[J] J. J. Ferreira;R. Katzenschlager;B. R. Bloem;U. Bonuccelli;D. Burn;G. Deuschl;E. Dietrichs;G. Fabbrini;A. Friedman;P. Kanovsky;V. Kostic;A. Nieuwboer;P. Odin;W. Poewe;O. Rascol;C. Sampaio;M. Schüpbach;E. Tolosa;C. Trenkwalder;A. Schapira;A. Berardelli;W. H. Oertel Eur J Neurol 2012,

What factors influence motor complications in Parkinson disease?: a 10-year prospective study.[J] García-Ruiz Pedro J;Del Val Javier;Fernández Ignacio Mahillo;Herranz Antonio Clinical neuropharmacology 2012,

Off spells and dyskinesias: pharmacologic management of motor complications.[J] Khan Tarannum S Cleveland Clinic journal of medicine 2012,

帕金森病运动并发症的认识与处理[J] 刘振国; 临床内科杂志 2011,

浅谈帕金森病治疗的并发症——异动症[J] 刘振国; 中华老年医学杂志 2006, 12

Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta‐analysis of levodopa‐controlled trials[J] M. Chondrogiorgi;A. Tatsioni;H. Reichmann;S. Konitsiotis Eur J Neurol 2014,

Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China.[J] Zhang Zhen-Xin;Chen Honglei;Chen Sheng-Di;Shao Ming;Sun Sheng-Gang;Qu Qiu-Min;Zhang Bao-Rong;Liu Yi-Ming;Xu Qun;Wan Xia;Li Ling;Wen Hong-Bo;Chen Xia;Chen Hai-Bo;Liu Zhen-Guo;Wang Jian;Wang Gang BMC research notes 2014,

Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease[J] C. Warren Olanow;Karl Kieburtz;Olivier Rascol;Werner Poewe;Anthony H. Schapira;Murat Emre;Helena Nissinen;Mika Leinonen;Fabrizio Stocchi; Mov Disord. 2013,

Nonmotor fluctuations in Parkinson disease: Severity and correlation with motor complications[J] Alexander Storch;Christine B. Schneider;Martin Wolz;Yannic Stürwald;Angelika Nebe;Per Odin;Andreas Mahler;Gerd Fuchs;Wolfgang H. Jost;K. Ray Chaudhuri;Rainer Koch;Heinz Reichmann;Georg Ebersbach Neurology 2013,

Summary of the recommendations of the EFNS / MDS ‐ ES review on therapeutic management of P arkinson's disease[J] J. J. Ferreira;R. Katzenschlager;B. R. Bloem;U. Bonuccelli;D. Burn;G. Deuschl;E. Dietrichs;G. Fabbrini;A. Friedman;P. Kanovsky;V. Kostic;A. Nieuwboer;P. Odin;W. Poewe;O. Rascol;C. Sampaio;M. Schüpbach;E. Tolosa;C. Trenkwalder;A. Schapira;A. Berardelli;W. H. Oertel Eur J Neurol 2012,

What factors influence motor complications in Parkinson disease?: a 10-year prospective study.[J] García-Ruiz Pedro J;Del Val Javier;Fernández Ignacio Mahillo;Herranz Antonio Clinical neuropharmacology 2012,

Off spells and dyskinesias: pharmacologic management of motor complications.[J] Khan Tarannum S Cleveland Clinic journal of medicine 2012,